| Citation: | Boyang Wang, Tingyu Zhang, Qingyuan Liu, Chayanis Sutcharitchan, Ziyi Zhou, Dingfan Zhang, Shao Li. Elucidating the role of artificial intelligence in drug development from the perspective of drug-target interactions[J]. Journal of Pharmaceutical Analysis, 2025, 15(3): 101144. doi: 10.1016/j.jpha.2024.101144
|
Drug development remains a critical issue in the field of biomedicine. With the rapid advancement of information technologies such as artificial intelligence (AI) and the advent of the big data era, AI-assisted drug development has become a new trend, particularly in predicting drug-target associations. To address the challenge of drug-target prediction, AI-driven models have emerged as powerful tools, offering innovative solutions by effectively extracting features from complex biological data, accurately modeling molecular interactions, and precisely predicting potential drug-target outcomes. Traditional machine learning (ML), network-based, and advanced deep learning architectures such as convolutional neural networks (CNNs), graph convolutional networks (GCNs), and transformers play a pivotal role. This review systematically compiles and evaluates AI algorithms for drug- and drug combination-target predictions, highlighting their theoretical frameworks, strengths, and limitations. CNNs effectively identify spatial patterns and molecular features critical for drug-target interactions. GCNs provide deep insights into molecular interactions via relational data, whereas transformers increase prediction accuracy by capturing complex dependencies within biological sequences. Network-based models offer a systematic perspective by integrating diverse data sources, and traditional ML efficiently handles large datasets to improve overall predictive accuracy. Collectively, these AI-driven methods are transforming drug-target predictions and advancing the development of personalized therapy. This review summarizes the application of AI in drug development, particularly in drug-target prediction, and offers recommendations on models and algorithms for researchers engaged in biomedical research. It also provides typical cases to better illustrate how AI can further accelerate development in the fields of biomedicine and drug discovery.
| [1] |
A.G. Atanasov, S.B. Zotchev, V.M. Dirsch, et al., Natural products in drug discovery: Advances and opportunities, Nat. Rev. Drug Discov. 20 (2021) 200-216.
|
| [2] |
C. Markey, S. Croset, O.R. Woolley, et al., Characterizing emerging companies in computational drug development, Nat. Comput. Sci. 4 (2024) 96-103.
|
| [3] |
J. Gao, Z. Xia, S. Gunasekar, et al., Precision drug delivery to the central nervous system using engineered nanoparticles, Nat. Rev. Mater. 9 (2024) 567-588.
|
| [4] |
P. Flynn, S. Suryaprakash, D. Grossman, et al., The antibody-drug conjugate landscape, Nat. Rev. Drug Discov. 23 (2024) 577-578.
|
| [5] |
R. Chen, S. Liu, J. Han, et al., Trends in rare disease drug development, Nat. Rev. Drug Discov. 23 (2024) 168-169.
|
| [6] |
S. Li, B. Zhang, Traditional Chinese medicine network pharmacology: Theory, methodology and application, Chin J Nat Med 11 (2013) 110-120.
|
| [7] |
A.L. Hopkins, Network pharmacology, Nat. Biotechnol. 25 (2007) 1110-1111.
|
| [8] |
A.L. Hopkins, Network pharmacology: The next paradigm in drug discovery, Nat. Chem. Biol. 4 (2008) 682-690.
|
| [9] |
R. Perez-Lopez, N. Ghaffari Laleh, F. Mahmood, et al., A guide to artificial intelligence for cancer researchers, Nat. Rev. Cancer 24 (2024) 427-441.
|
| [10] |
P. Zhang, B. Wang, S. Li, Network-based cancer precision prevention with artificial intelligence and multi-omics, Sci. Bull. 68 (2023) 1219-1222.
|
| [11] |
M. Aboy, W.N. Price, S. Raker, et al., The sufficiency of disclosure of medical artificial intelligence patents, Nat. Biotechnol. 42 (2024) 839-845.
|
| [12] |
M. Krishnamoorthy, M.W. Sjoding, J. Wiens, Off-label use of artificial intelligence models in healthcare, Nat. Med. 30 (2024) 1525-1527.
|
| [13] |
A. Lucas, A. Revell, K.A. Davis, Artificial intelligence in epilepsy-applications and pathways to the clinic, Nat. Rev. Neurol. 20 (2024) 319-336.
|
| [14] |
K. Huang, T. Fu, W. Gao, et al., Artificial intelligence foundation for therapeutic science, Nat. Chem. Biol. 18 (2022) 1033-1036.
|
| [15] |
C. Xu, S.A. Solomon, W. Gao, Artificial intelligence-powered electronic skin, Nat. Mach. Intell. 5 (2023) 1344-1355.
|
| [16] |
C. Both, N. Dehmamy, R. Yu, et al., Accelerating network layouts using graph neural networks, Nat. Commun. 14 (2023), 1560.
|
| [17] |
M.A. Reyna, D. Haan, M. Paczkowska, et al., Pathway and network analysis of more than 2500 whole cancer genomes, Nat. Commun. 11 (2020), 729.
|
| [18] |
W. Zhou, K. Yang, J. Zeng, et al., FordNet: Recommending traditional Chinese medicine formula via deep neural network integrating phenotype and molecule, Pharmacol. Res. 173 (2021), 105752.
|
| [19] |
N.S. Nagra, L. van der Veken, E. Stanzl, et al., The company landscape for artificial intelligence in large-molecule drug discovery, Nat. Rev. Drug Discov. 22 (2023) 949-950.
|
| [20] |
P. Zhang, D. Zhang, W. Zhou, et al., Network pharmacology: Towards the artificial intelligence-based precision traditional Chinese medicine, Brief. Bioinform. 25 (2023), bbad518.
|
| [21] |
M.W. Mullowney, K.R. Duncan, S.S. Elsayed, et al., Artificial intelligence for natural product drug discovery, Nat. Rev. Drug Discov. 22 (2023) 895-916.
|
| [22] |
N. Fleming, How artificial intelligence is changing drug discovery, Nature 557 (2018) S55-S57.
|
| [23] |
J. Jimenez-Luna, F. Grisoni, G. Schneider, Drug discovery with explainable artificial intelligence, Nat. Mach. Intell. 2 (2020) 573-584.
|
| [24] |
Y. You, X. Lai, Y. Pan, et al., Artificial intelligence in cancer target identification and drug discovery, Signal Transduct. Target. Ther. 7 (2022), 156.
|
| [25] |
P. Schneider, W.P. Walters, A.T. Plowright, et al., Rethinking drug design in the artificial intelligence era, Nat. Rev. Drug Discov. 19 (2020) 353-364.
|
| [26] |
F. Urbina, F. Lentzos, C. Invernizzi, et al., Dual use of artificial-intelligence-powered drug discovery, Nat. Mach. Intell. 4 (2022) 189-191.
|
| [27] |
X. Lai, X. Wang, Y. Hu, et al., Editorial: Network pharmacology and traditional medicine, Front. Pharmacol. 11 (2020), 1194.
|
| [28] |
G. Rosenberger, W. Li, M. Turunen, et al., Network-based elucidation of colon cancer drug resistance mechanisms by phosphoproteomic time-series analysis, Nat. Commun. 15 (2024), 3909.
|
| [29] |
B.A. Maron, L. Altucci, J.L. Balligand, et al., A global network for network medicine, NPJ Syst. Biol. Appl. 6 (2020), 29.
|
| [30] |
C. Wallis, How artificial intelligence will change medicine, Nature 576 (2019), S48.
|
| [31] |
T. Kenakin, Know your molecule: Pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition, Nat. Rev. Drug Discov. 23 (2024) 626-644.
|
| [32] |
S. Li, Network pharmacology evaluation method guidance - draft, World J. Tradit. Chin. Med. 7 (2021) 146-154.
|
| [33] |
Z. Wang, X. Wang, D. Zhang, et al., Traditional Chinese medicine network pharmacology: Development in new era under guidance of network pharmacology evaluation method guidance, Zhongguo Zhong Yao Za Zhi, 47 (2022) 7-17.
|
| [34] |
Y. Huang, S. Li, Detection of characteristic sub pathway network for angiogenesis based on the comprehensive pathway network, BMC Bioinform. 11 (2010), S32.
|
| [35] |
S. Li, Network target: A starting point for traditional Chinese medicine network pharmacology, Zhongguo Zhong Yao Za Zhi 36 (2011) 2017-2020.
|
| [36] |
X. Wu, R. Jiang, M.Q. Zhang, et al., Network-based global inference of human disease genes, Mol. Syst. Biol. 4 (2008), 189.
|
| [37] |
S. Zhao, S. Li, Network-based relating pharmacological and genomic spaces for drug target identification, PLoS One 5 (2010), e11764.
|
| [38] |
F. Cheng, R.J. Desai, D.E. Handy, et al., Network-based approach to prediction and population-based validation of in silico drug repurposing, Nat. Commun. 9 (2018), 2691.
|
| [39] |
J. Kong, H. Lee, D. Kim, et al., Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients, Nat. Commun. 11 (2020), 5485.
|
| [40] |
D. Bang, S. Lim, S. Lee, et al., Biomedical knowledge graph learning for drug repurposing by extending guilt-by-association to multiple layers, Nat. Commun. 14 (2023), 3570.
|
| [41] |
Y. Luo, X. Zhao, J. Zhou, et al., A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information, Nat. Commun. 8 (2017), 573.
|
| [42] |
J. Zhu, J. Wang, X. Wang, et al., Prediction of drug efficacy from transcriptional profiles with deep learning, Nat. Biotechnol. 39 (2021) 1444-1452.
|
| [43] |
A.S. Rifaioglu, E. Nalbat, V. Atalay, et al., DEEPScreen: High performance drug-target interaction prediction with convolutional neural networks using 2-D structural compound representations, Chem. Sci. 11 (2020) 2531-2557.
|
| [44] |
G.K. Kanev, Y. Zhang, A.J. Kooistra, et al., Predicting the target landscape of kinase inhibitors using 3D convolutional neural networks, PLoS Comput. Biol. 19 (2023), e1011301.
|
| [45] |
T. Zhao, Y. Hu, L.R. Valsdottir, et al., Identifying Drug-Target Interactions based on graph convolutional network and deep neural network, Brief. Bioinform. 22 (2021) 2141-2150.
|
| [46] |
Z. Liu, Q. Chen, W. Lan, et al., GADTI: Graph autoencoder approach for DTI prediction from heterogeneous network, Front. Genet. 12 (2021), 650821.
|
| [47] |
S. Zhang, K. Yang, Z. Liu, et al., DrugAI: A multi-view deep learning model for predicting drug-target activating/inhibiting mechanisms, Brief. Bioinform. 24 (2023), bbac526.
|
| [48] |
S. Hou, P. Zhang, K. Yang, et al., Decoding multilevel relationships with the human tissue-cell-molecule network, Brief. Bioinform. 23 (2022), bbac170.
|
| [49] |
K. Huang, C. Xiao, L.M. Glass, et al., MolTrans: Molecular Interaction Transformer for drug-target interaction prediction, Bioinformatics 37 (2021) 830-836.
|
| [50] |
L. Zhang, C. Wang, X. Chen, Predicting drug-target binding affinity through molecule representation block based on multi-head attention and skip connection, Brief. Bioinform. 23 (2022), bbac468.
|
| [51] |
Z. Zhu, X. Zheng, G. Qi, et al., Drug-target binding affinity prediction model based on multi-scale diffusion and interactive learning, Expert. Syst. Appl. 255 (2024), 124647.
|
| [52] |
Z. Zhu, Z. Yao, X. Zheng, et al., Drug-target affinity prediction method based on multi-scale information interaction and graph optimization. Comput. Biol. Me. 167 (2023), 107621.
|
| [53] |
M. Lennox, N. Robertson, B. Devereux, Modelling drug-target binding affinity using a BERT based graph neural network, IEEE Eng. Med. Biol. Mag. (2021), 4348-4353.
|
| [54] |
C.V. Theodoris, L. Xiao, A. Chopra, et al., Transfer learning enables predictions in network biology, Nature 618 (2023) 616-624.
|
| [55] |
F. Marchetti, E. Moroni, A. Pandini, et al., Machine learning prediction of allosteric drug activity from molecular dynamics, 12 (2021) 3724-3732.
|
| [56] |
A. Salimi, J.H. Lim, J.H. Jang, et al., The use of machine learning modeling, virtual screening, molecular docking, and molecular dynamics simulations to identify potential VEGFR2 kinase inhibitors, Sci. Rep. 12 (2022), 18825.
|
| [57] |
M. Yasir, J. Park, E.T. Han, et al., Machine learning-based drug repositioning of novel Janus kinase 2 inhibitors utilizing molecular docking and molecular dynamic simulation, J. Chem. Inf. Model. 63 (2023) 6487-6500.
|
| [58] |
H. Zhang, T. Zhang, K.M. Saravanan, et al., DeepBindBC: A practical deep learning method for identifying native-like protein-ligand complexes in virtual screening, Methods 205 (2022) 247-262.
|
| [59] |
H. Zhang, J. Li, K.M. Saravanan, et al., An integrated deep learning and molecular dynamics simulation-based screening pipeline identifies inhibitors of a new cancer drug target TIPE2, Front. Pharmacol. 12 (2021), 772296.
|
| [60] |
J. Jimenez, M. Skalic, G. Martinez-Rosell, et al., KDEEP: Protein-ligand absolute binding affinity prediction via 3D-convolutional neural networks, J. Chem. Inf. Model. 58 (2018) 287-296.
|
| [61] |
M. Ragoza, J. Hochuli, E. Idrobo, et al., Protein-ligand scoring with convolutional neural networks, J. Chem. Inf. Model. 57 (2017) 942-957.
|
| [62] |
M.M. Stepniewska-Dziubinska, P. Zielenkiewicz, P. Siedlecki, Development and evaluation of a deep learning model for protein-ligand binding affinity prediction, Bioinformatics 34 (2018) 3666-3674.
|
| [63] |
D. Jones, H. Kim, X. Zhang, et al., Improved protein-ligand binding affinity prediction with structure-based deep fusion inference, J. Chem. Inf. Model. 61 (2021) 1583-1592.
|
| [64] |
S. Moon, W. Zhung, S. Yang, et al., PIGNet: A physics-informed deep learning model toward generalized drug-target interaction predictions, Chem. Sci. 13 (2022) 3661-3673.
|
| [65] |
L. Guo, T. Qiu, J. Wang, ViTScore: A novel three-dimensional vision transformer method for accurate prediction of protein-ligand docking poses, IEEE Trans. Nanobiosci. 22 (2023) 734-743.
|
| [66] |
Y. Yi, X. Wan, Y. Bian, et al., ETDock: A novel equivariant transformer for protein-ligand docking, arXiv. https://doi.org/10.48550/arXiv.2310.08061.
|
| [67] |
Y. Wang, S. Wu, Y. Duan, et al., A point cloud-based deep learning strategy for protein-ligand binding affinity prediction, Brief. Bioinform. 23 (2022), bbab474.
|
| [68] |
Z. Zhu, Z. Yao, G. Qi, et al., Associative learning mechanism for drug-target interaction prediction, CAAI TRIT. 8 (2023) 1558-1577.
|
| [69] |
Y. Guo, C. Bao, D. Ma, et al., Network-based combinatorial CRISPR-Cas9 screens identify synergistic modules in human cells, ACS Synth. Biol. 8 (2019) 482-490.
|
| [70] |
H. Qiao, F. Wang, R. Xu, et al., An efficient and multiple target transgenic RNAi technique with low toxicity in Drosophila, Nat. Commun. 9 (2018), 4160.
|
| [71] |
S. Li, B. Zhang, N. Zhang, Network target for screening synergistic drug combinations with application to traditional Chinese medicine, BMC Syst. Biol. 5 (2011), S10.
|
| [72] |
S. Li, B. Zhang, D. Jiang, et al., Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae, BMC Bioinformatics, 11 (2010), S6.
|
| [73] |
S. Zhao, S. Li, A co-module approach for elucidating drug-disease associations and revealing their molecular basis, Bioinformatics 28 (2012) 955-961.
|
| [74] |
F. Cheng, I.A. Kovacs, A.L. Barabasi, Network-based prediction of drug combinations, Nat. Commun. 10 (2019), 1197.
|
| [75] |
J. Zhao, C. Lv, Q. Wu, et al., Computational systems pharmacology reveals an antiplatelet and neuroprotective mechanism of Deng-Zhan-Xi-Xin injection in the treatment of ischemic stroke, Pharmacol. Res. 147 (2019), 104365.
|
| [76] |
A.I. Casas, A.A. Hassan, S.J. Larsen, et al., From single drug targets to synergistic network pharmacology in ischemic stroke, PNAS 116 (2019) 7129-7136.
|
| [77] |
H.I. Kuru, O. Tastan, A.E. Cicek, MatchMaker: A deep learning framework for drug synergy prediction, Trans. IEEE/ACM Comput. Biol. Bioinform. 19 (2022) 2334-2344.
|
| [78] |
Y.C. Tang, A. Gottlieb, SynPathy: Predicting drug synergy through drug-associated pathways using deep learning, Mol. Cancer Res. 20 (2022) 762-769.
|
| [79] |
I.F. do Valle, H.G. Roweth, M.W. Malloy, et al., Network medicine framework shows that proximity of polyphenol targets and disease proteins predicts therapeutic effects of polyphenols, Nat. Food 2 (2021) 143-155.
|
| [80] |
S. Li, R. Wang, Y. Zhang, et al., Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS, Am. J. Chinese Med. 34 (2006) 937-947.
|
| [81] |
H. Xu, S. Li, J. Liu, et al., Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19, Proc Natl Acad Sci U. S. A. 120 (2023), e2301775120.
|
| [82] |
B. Wang, W. Zhou, H. Zhang, et al., Exploring the effect of Weifuchun capsule on the toll-like receptor pathway mediated HES6 and immune regulation against chronic atrophic gastritis, J. Ethnopharmacol. 303 (2023), 115930.
|
| [83] |
W. Zhou, H. Zhang, X. Wang, et al., Network pharmacology to unveil the mechanism of Moluodan in the treatment of chronic atrophic gastritis, Phytomedicine 95 (2022), 153837.
|
| [84] |
B. Wang, D. Zhang, T. Zhang, et al., Uncovering the mechanisms of Yi Qi Tong Qiao Pill in the treatment of allergic rhinitis based on Network target analysis, Chin. Med. 18 (2023), 88.
|
| [85] |
C. Zhang, Y. Lu, T. Zang, CNN-DDI: A learning-based method for predicting drug-drug interactions using convolution neural networks, BMC Bioinform. 23 (2022), 88.
|
| [86] |
Z. Yang, K. Tong, S. Jin, et al., CNN-Siam: Multimodal Siamese CNN-based deep learning approach for drug-drug interaction prediction, BMC Bioinform. 24 (2023), 110.
|
| [87] |
A. Kucukosmanoglu, S. Scoarta, M. Houweling, et al., A real-world toxicity atlas shows that adverse events of combination therapies commonly result in additive interactions, Clin. Cancer Res. 30 (2024) 1685-1695.
|
| [88] |
J. Han, M. Kang, S. Lee, DRSPRING Graph convolutional network (GCN)-Based drug synergy prediction utilizing drug-induced gene expression profile, Comput. Biol. Med. 174 (2024), 108436.
|
| [89] |
C. Gao, S. Yin, H. Wang, et al., Medical-knowledge-based graph neural network for medication combination prediction, IEEE Trans. Neural Netw. Learn. Syst. (2023).
|
| [90] |
X. Chen, X. Liu, J. Wu, GCN-BMP: Investigating graph representation learning for DDI prediction task, Methods 179 (2020) 47-54.
|
| [91] |
Y. Guo, H. Hu, W. Chen, et al., SynergyX: A multi-modality mutual attention network for interpretable drug synergy prediction, Brief. Bioinform. 25 (2024), bbae015.
|
| [92] |
W. Alam, H. Tayara, K.T. Chong, Unlocking the therapeutic potential of drug combinations through synergy prediction using graph transformer networks, Comput. Biol. Med. 170 (2024), 108007.
|
| [93] |
S. Lin, G. Zhang, D. Wei, et al., DeepPSE: Prediction of polypharmacy side effects by fusing deep representation of drug pairs and attention mechanism, Comput. Biol. Med. 149 (2022), 105984.
|
| [94] |
S. Lin, Y. Wang, L. Zhang, et al., MDF-SA-DDI: Predicting drug-drug interaction events based on multi-source drug fusion, multi-source feature fusion and transformer self-attention mechanism, Brief. Bioinform. 23 (2022), bbab421.
|
| [95] |
Y. Hong, P. Luo, S. Jin, et al., LaGAT: Link-aware graph attention network for drug-drug interaction prediction, Bioinformatics 38 (2022) 5406-5412.
|
| [96] |
L. Huang, J. Lin, X. Li, et al., EGFI: Drug-drug interaction extraction and generation with fusion of enriched entity and sentence information, Brief. Bioinform. 23 (2022), bbab451.
|
| [97] |
T. Li, S. Shetty, A. Kamath, et al., CancerGPT: Few-shot drug pair synergy prediction using large pre-trained language models, arXiv. 2024. https://doi.org/10.48550/arXiv.2304.10946.
|
00241-7cda3850e-0e27-4cbc-83b9-ddec6291398c.jpg)
Figures(1)
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad: